Omeros Corporation (OMER) News

Omeros Corporation (OMER): $3.58

0.49 (+15.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OMER to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter OMER News Items

OMER News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest OMER News From Around the Web

Below are the latest news stories about Omeros Corp that investors may wish to consider to help them evaluate OMER as an investment opportunity.

Needham Keeps Their Hold Rating on Omeros (OMER)

E ratio of -3.56.

Howard Kim on TipRanks | March 2, 2022

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include

Business Wire | March 1, 2022

Omeros Corporation''s (OMER) CEO Greg Demopulos On Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | March 1, 2022

Omeros Non-GAAP EPS of -$0.37 misses by $0.31

Omeros press release (OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31.At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available…

Seeking Alpha | March 1, 2022

How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own?

Every investor in Omeros Corporation ( NASDAQ:OMER ) should be aware of the most powerful shareholder groups...

Yahoo | March 1, 2022

Why Earnings Season Could Be Great for Omeros (OMER)

Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 28, 2022

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022

SEATTLE, February 24, 2022--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Yahoo | February 24, 2022

Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next?

Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.34 million during the last session, with the companys beta value hitting 0.63. At the close of trading, the stocks price was $6.32, to imply a decrease of -1.86% or -$0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -277.37% down since that peak Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next? Read More »

Marketing Sentinel | February 12, 2022

Bellevue Asset Management, Llc Buys First Trust Low Duration Mortgage Opportunities ET, eBay ...

Investment company Bellevue Asset Management, Llc (Current Portfolio) buys First Trust Low Duration Mortgage Opportunities ET, eBay Inc, Omeros Corp, Realty Income Corp, Trane Technologies PLC, sells Bristol-Myers Squibb Co, General Electric Co, Timberland Bancorp Inc, Ford Motor Co, United Parcel Service Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bellevue Asset Management, Llc.

Yahoo | February 3, 2022

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER ) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised Full story available on Benzinga.com

Benzinga | January 20, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8049 seconds.